PLoS ONE · 2015 · 20 citations · 25 references
MedicineNuclear MedicineOncologyImmunotherapyMolecular OncologyMonoclonal AntibodiesAntibody CharacterizationCancer ImmunotherapyOvarian CancerOvarian Cancer PharmacotherapyRecombinant AntibodiesTumor AntigensAntibody-based Radionuclide TherapyBiomolecular Binding AffinityHumanized ModelsMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyNormal Tissue UptakeSingle-photon EmissionTumor Targeting Specificity
The aim of this preclinical study was to evaluate the characteristics of the monoclonal antibody Rebmab200, which is a humanized version of the ovarian-specific murine antibody MX35. This investigation contributes to the foundation for future clinical α-radioimmunotherapy of minimal residual ovarian cancer with 211At-Rebmab200. Here, the biodistribution of 211At-Rebmab200 was evaluated, as was the utility of 99mTc-Rebmab200 for bioimaging. Rebmab200 was directly compared with its murine counterpart MX35 in terms of its in-vitro capacity for binding the immobilized NaPi2B epitope and live cells; we also assessed its biodistribution in nude mice carrying subcutaneous OVCAR-3 tumors. Tumor antigen and cell binding were similar between Rebmab200 and murine MX35, as was biodistribution, including normal tissue uptake and in-vivo tumor binding. We also demonstrated that 99mTc-Rebmab200 can be used for single-photon emission computed tomography of subcutaneous ovarian carcinomas in tumor-bearing mice. Taken together, our data support the further development of Rebmab200 for radioimmunotherapy and diagnostics.
25
Michael R. Zalutsky, David A. Reardon, Gamal Akabani et al. · Journal of Nuclear Medicine · 2007 · 396 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Håkan Andersson, Elin Cederkrantz, Tom Bäck et al. · Journal of Nuclear Medicine · 2009 · 288 citations · Full text
Medicine, Oncology, Pharmacokinetics +17
Lea Olive Tchouate Gainkam, Lieven Huang, Vicky Caveliers et al. · Journal of Nuclear Medicine · 2008 · 218 citations · Full text
Medicine, Oncology, Pharmacology +17